Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.
What shared decision-making means
Shared decision-making is a clinical practice in which the clinician and patient collaborate to make decisions that incorporate the best available clinical evidence, the patient's values and preferences, and individualized risk-benefit assessment. The classic SDM framework involves three steps[1]A:
- Choice talk — ensure the patient knows that reasonable alternatives exist and that their preferences matter
- Option talk — describe the alternatives in detail, including outcomes, risks, and trade-offs, using decision-support tools as appropriate
- Decision talk — elicit the patient's values and preferences, integrate them with the clinical evidence, and reach a shared decision
SDM is most appropriate when there are reasonable alternatives with substantively different benefit/risk profiles and where patient values plausibly affect the optimal choice. Many TNBC decisions fit this profile.
TNBC decisions where SDM is especially valuable
Surgical approach
Lumpectomy + radiation vs mastectomy with or without reconstruction is a fundamental choice. The outcome literature (NSABP B-06 and follow-up) shows equivalent survival, leaving patient values about body image, recovery, future surveillance, and partner relationship as critical inputs. For BRCA mutation carriers, bilateral mastectomy with risk-reducing intent adds complexity: contralateral cancer risk reduction must be weighed against quality-of-life impact.
Risk-reducing oophorectomy timing
BRCA1/2 mutation carriers face decisions about risk-reducing salpingo-oophorectomy (RRSO) for ovarian cancer prevention, with timing implications for fertility, surgical menopause, and ongoing cancer surveillance. Patient values about future childbearing, surgical menopause symptoms, and long-term hormone replacement weigh heavily.
Fertility preservation
Pre-treatment fertility preservation requires weighing chemotherapy delay (2–3 weeks for stimulation), cost, success probability, and partner/family considerations. Values about future childbearing are central.
Adjuvant regimen intensity
KEYNOTE-522 is the standard for higher-risk TNBC but carries substantial toxicity including persistent irAEs. Patient values about treatment intensity tolerance and willingness to accept long-term immune-related risk for absolute benefit gain inform the discussion.
Adjuvant therapy completion
Treatment discontinuation is common and consequential. SDM about persisting through toxicity, dose modifications, and supportive care can affect completion rates.
First-line metastatic regimen
Choice between chemo + pembrolizumab (PD-L1+), PARP inhibitor monotherapy (BRCA-mutant), and other options involves trade-offs around toxicity profile, oral vs IV administration, monitoring requirements, and quality of life.
End-of-life and advance care planning
Late-line decisions about additional therapy vs supportive care alone involve deeply personal values about quality vs quantity of life. Early advance care planning conversations, ideally before crisis, improve concordance with patient values.
Decision aids and decision support tools
Patient decision aids (PtDAs) are structured tools that help patients understand options, risks, benefits, and personal values. Cochrane systematic review of PtDAs across conditions demonstrates[2]A:
- Improved knowledge about options
- More accurate risk perception
- Greater clarity about personal values
- Reduced decisional conflict
- Greater patient participation in decision-making
- No detrimental effect on clinical outcomes; sometimes improved
Specific decision aids relevant to TNBC:
- BRCAtool, BRCA decision aid — for BRCA-positive patients considering risk-reducing surgery
- Mastectomy/lumpectomy decision aids — multiple validated tools for breast cancer surgical decision
- Reconstruction decision aids — for patients choosing between reconstruction options
- Fertility preservation decision aids — for young patients considering pre-treatment fertility preservation
- General oncology SDM tools — Option Grid format, brief decision-support summaries
Available platforms include Healthwise patient decision aids, the Mayo Clinic Shared Decision Making Center decision aids, and the Ottawa Hospital Research Institute decision aid library.
Values elicitation methods
Approaches to eliciting patient values in clinical encounters:
- Open-ended questions — "What's most important to you about your treatment?" "What concerns you most about the options?"
- Values clarification exercises — structured tools rating importance of outcomes (survival, quality of life, body image, etc.)
- Trade-off scenarios — presenting hypothetical choices that surface preferences
- Best-case/worst-case framing — useful for end-of-life conversations
- Concordance check — verifying that the proposed plan aligns with elicited values
Cultural variation in decision-making style is important. Some patients prefer to defer to clinician recommendation; others want full information and decision authority; many prefer collaborative discussion. SDM should accommodate this variation rather than impose a single approach.
Information asymmetry challenges
TNBC SDM faces particular challenges from information asymmetry:
- Biomarker biology (PD-L1, BRCA, HER2-low) is unfamiliar to most patients
- Statistical concepts (hazard ratios, NNT, confidence intervals) are difficult to communicate effectively
- Time pressure of cancer decisions limits opportunity for full deliberation
- Emotional distress at diagnosis impairs cognitive processing of complex information
- Trial vs guideline-concordant care complexity can be difficult to convey
- Insurance and cost considerations interact with clinical recommendations
Communication strategies
Evidence-based communication strategies for oncology SDM:
- Teach-back method — asking patient to explain options in their own words to verify understanding
- Pictorial risk presentation — icon arrays and bar charts improve comprehension over numerical-only formats
- Absolute vs relative risk framing — absolute risks are more accurately interpreted than relative risk reductions
- Time-anchored framing — "out of 100 patients like you, X will have outcome Y over 5 years" rather than abstract statistics
- Plain language — avoiding jargon when possible; defining unavoidable terminology
- Visual aids — diagrams, charts, illustrations
- Recordings or written summaries — allowing patient to review information later
- Companion involvement — partner or family members can support decision-making
- Multiple sessions — complex decisions benefit from staged conversations rather than single encounters
SDM in second opinions and care transitions
Second-opinion consultations are an opportunity for SDM reinforcement; patients seeking second opinions often face decision conflict. Care transitions (community oncology to academic center, between subspecialties, into clinical trial) involve information transfer and may require SDM about clinical-trial enrollment.
Implementation challenges
Barriers to systematic SDM implementation in oncology:
- Time constraints in clinical workflow
- Reimbursement structures that don't prioritize SDM time
- Clinician training in SDM techniques is inconsistent
- Decision-aid integration into electronic health record workflow
- Cultural and language barriers particularly affect underserved populations
- Health literacy variation requires tailored approach
Promising approaches include pre-visit decision aid completion, decision support sessions with trained navigators or social workers, telehealth-based SDM consultations, and integrated decision support in patient portals.
Evidence table
| Decision context | SDM intervention | Evidence |
|---|---|---|
| Surgical approach | Validated decision aids | Improved knowledge, reduced conflict |
| BRCA risk-reducing surgery | Genetic counseling + decision aid | Improved values clarity |
| Reconstruction choice | Visual + outcome decision aids | Better satisfaction concordance |
| Fertility preservation | Structured pre-treatment consultation | Higher rates of values-concordant choice |
| End-of-life planning | Serious illness conversation guide | Better care-preference concordance |
| Metastatic regimen choice | Decision aids in development | Limited TNBC-specific evidence |
Open questions and active investigation
- TNBC-specific decision aids. Most existing breast cancer decision aids don't specifically address TNBC biomarker-driven choices; TNBC-specific decision aids are being developed.
- Biomarker explanation tools. Effective communication of PD-L1, BRCA, HER2-low concepts to patients with limited prior biology background requires specialized tools.
- SDM impact on outcomes. Whether SDM improves clinical outcomes (vs only decisional satisfaction) is being studied; some evidence suggests better adherence and completion.
- Cultural adaptation of decision aids. Most decision aids are developed for predominantly White, English-speaking populations; cultural adaptation is essential for equitable implementation.
- Integration with AI-based prediction tools. Individualized risk and benefit prediction (potentially from ML models) could inform SDM but raises new communication challenges around model uncertainty and interpretation.
- SDM in clinical trial enrollment. SDM about trial participation is distinct from SDM about standard-of-care choices and requires specific decision-support approaches.
- Patient-facing AI tools. LLM-based decision-support chatbots are being explored; effectiveness and safety in cancer care require careful evaluation.
For access barriers that intersect with SDM, see the (forthcoming) access and affordability synthesis. For genetic counseling components of BRCA-related decisions, see the (forthcoming) genetic counseling synthesis.
References
Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.
- Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi:10.1007/s11606-012-2077-6. ↩
- Stacey D, Légaré F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4(4):CD001431. doi:10.1002/14651858.CD001431.pub5. ↩
Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.